Royalty Pharma

Elan Risking $2 Billion If Royalty Pharma Walks: Real M&A
Elan Risking $2 Billion If Royalty Pharma Walks: Real M&A
Bloomberg
Elan
M&A
Royalty Pharma
Flag link:
Elan shareholders sort through improving deals as vote looms
Elan shareholders sort through improving deals as vote looms
Fierce Pharma
Elan
M&A
Royalty Pharma
Flag link:
Elan Board Rejects $6.7 Billion Royalty Pharma Offer
Elan Board Rejects $6.7 Billion Royalty Pharma Offer
Bloomberg
Elan
Royalty Pharma
M&A
Flag link:
Royalty Pharma ups bid for Irish drug firm to $8bn
Royalty Pharma ups bid for Irish drug firm to $8bn
Trade Arabia
Royalty Pharma
M&A
Ireland
international
Elan
Flag link:
Royalty Pharma Raises Elan Offer to $6.7 Billion Plus CVR
Royalty Pharma Raises Elan Offer to $6.7 Billion Plus CVR
Bloomberg
Royalty Pharma
Elan
M&A
Flag link:
Royalty Pharma Extends $6.4B Takeover Over for Elan
Royalty Pharma Extends $6.4B Takeover Over for Elan
Bloomberg
Elan
Royalty Pharma
M&A
Flag link:
U.S. court freezes Royalty's bid for drugmaker Elan
U.S. court freezes Royalty's bid for drugmaker Elan
Reuters
Royalty Pharma
Elan
M&A
Flag link:
Elan CEO Says Alternatives Exist If Shareholders Reject Deals
Elan CEO Says Alternatives Exist If Shareholders Reject Deals
Bloomberg
Elan
Theravance
Royalty Pharma
M&A
Flag link:
Royalty Pharma offer for Elan gets little support
Royalty Pharma offer for Elan gets little support
Yahoo/AP
Royalty Pharma
Elan
Flag link:
Royalty Pharma eases condition for Elan offer
Royalty Pharma eases condition for Elan offer
Yahoo/AP
Royalty Pharma
Elan
M&A
Flag link:
Royalty ups bid as Elan unveils acquisitions
Royalty ups bid as Elan unveils acquisitions
Pharma Times, UK
Elan
M&A
Royalty Pharma
Flag link:
Elan Makes Two Acquisitions for $380 Million
Elan Makes Two Acquisitions for $380 Million
Bloomberg
M&A
Royalty Pharma
Elan
AOP Orphan
NewBridge Pharmaceuticals
Flag link:
Did Elan Just Overpay On Theravance To Spurn Its Hostile Suitor?
Did Elan Just Overpay On Theravance To Spurn Its Hostile Suitor?
Forbes
Theravance
GSK
Elan
Royalty Pharma
Flag link:
Elan considered buying Royalty before becoming its target
Elan considered buying Royalty before becoming its target
Reuters
Elan
Royalty Pharma
M&A
Flag link:
Royalty Pharma stands by reduced Elan bid
Royalty Pharma stands by reduced Elan bid
Reuters
Royalty Pharma
M&A
Elan
Flag link:
Elan sees sales of prized Tysabri drug rise sharply
Elan sees sales of prized Tysabri drug rise sharply
Reuters
Elan
Royalty Pharma
M&A
Tysabri
Flag link:
Elan rejects Royalty bid as grossly undervaluing its prospects
Elan rejects Royalty bid as grossly undervaluing its prospects
Reuters
Royalty Pharma
Elan
M&A
Flag link:
Elan buyback priced at $11.25 reduces Royalty bid
Elan buyback priced at $11.25 reduces Royalty bid
Reuters
Royalty Pharma
Elan
stock buyback
Flag link:
Royalty Pharma sweetens offer for Elan
Royalty Pharma sweetens offer for Elan
Reuters
Elan
M&A
Royalty Pharma
Flag link:
Elan shareholders approve buyback as Royalty fight heats up
Elan shareholders approve buyback as Royalty fight heats up
Reuters
Elan
Royalty Pharma
Flag link:

Pages